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ABSTRACT
The Vitek-2 extended-spectrum b-lactamase (ESBL) test was assessed using a collection of 94 ESBL-
positive and 71 ESBL-negative non-duplicate isolates of Enterobacteriaceae. These isolates produced a
wide diversity of well-characterised b-lactamases, including 61 different ESBLs, two class A carbapen-
emases and various species-specific b-lactamases. ESBL detection was performed using (i) the
conventional synergy test as recommended by the Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise
de Microbiologie, (ii) the CLSI phenotypic confirmatory test for ESBLs, and (iii) the Vitek-2 ESBL test.
For Escherichia coli and klebsiellae, the sensitivity ⁄ specificity values were 97.3% ⁄ 96.9% for the synergy
test, 91.8% ⁄ 100% for the CLSI phenotypic confirmatory test, and 91.8% ⁄ 100% for the Vitek-2 ESBL
test. For other organisms, the sensitivity ⁄ specificity values were 100% ⁄ 97.4% for the synergy test,
90.5% ⁄ 100% for the CLSI phenotypic confirmatory test, and 90.5% ⁄ 100% for the Vitek-2 ESBL test. The
Vitek-2 ESBL test seemed to be an efficient method for routine detection of ESBL-producing isolates of
Enterobacteriaceae, including isolates producing AmpC-type enzymes.
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INTRODUCTION
Extended-spectrum b-lactamases (ESBLs) are a
large group (>150) of b-lactamases that confer
resistance to the oxyimino-cephalosporins and
monobactams [1,2]. The first ESBLs described
were derived from TEM and SHV penicillinases
following a few amino-acid substitutions [2].
More recently, non-TEM and non-SHV ESBLs
have been reported, including ceftazidimases of
the PER, VEB and GES ⁄ IBC types, and cefotaxi-
mases of the BES-1 and CTX-M types. ESBL
production was originally detected in Klebsiella
pneumoniae, but is now reported in all Enterobac-
teriaceae isolated commonly from clinical infec-
tions [1,3].
Some ESBL-producing organisms are suscepti-
ble to cephalosporins according to conventional
breakpoints; indeed, it has been reported that
c. 40% of ESBL-producing organisms are suscep-
tible to at least one oxyimino-b-lactam, and that
20% are susceptible to all oxyimino-b-lactams
according to CLSI breakpoints [4]. However,
treatment failure has occurred with oxyimino-
cephalosporins even when MICs are within the
susceptible range [4]. Various tests have been
developed to improve ESBL detection, all of
which are based on the activity of ESBLs against
oxyimino-cephalosporins and their susceptibility
to inhibitors such as clavulanate. According to
CLSI recommendations, Escherichia coli, K. pneu-
moniae, Klebsiella oxytoca and Proteus mirabilis
isolates are ESBL producers if the MIC of cefo-
taxime or ceftazidime is decreased by at least
three two-fold dilutions in the presence of clavul-
anate, or if the zone diameter around a disk of one
of these cephalosporins is increased by at least
5 mm in the presence of clavulanate [5]. This
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synergy between oxyimino-cephalosporins and
clavulanate is also used in the double-disk syn-
ergy test recommended for use in France. An
extension of the edge of the inhibition zone of a
disk containing ceftazidime, cefotaxime, ceftriax-
one, aztreonam, cefpirome or cefepime towards
the disk containing clavulanate is considered to
indicate synergy (http://www.sfm.asso.fr).
The Vitek-2 ESBL test is based on a comparison
of the inhibitory effects of ceftazidime, cefotaxime
and cefepime, alone and in combination with
clavulanate. The final interpretation of results by
the automated Vitek-2 system is based on the
Vitek-2 ESBL test results and an analysis of MIC
distributions of several b-lactam antibiotics. The
aim of the present study was to evaluate the
ability of the Vitek-2 ESBL test to detect ESBL
production in a large collection of non-duplicate
isolates of Enterobacteriaceae, including non-
E. coli and non-Klebsiella spp., that were resistant
to oxyimino-cephalosporins. The collection of
isolates produced a wide diversity of well-char-
acterised b-lactamases, including 61 different
ESBLs, two class A carbapenemases, and various
species-specific b-lactamases, particularly AmpC-
type enzymes.
MATERIALS AND METHODS
Bacterial isolates
The study used a collection of 165 non-duplicate clinical
isolates of Enterobacteriaceae producing well-characterised
b-lactamases (Table 1). The collection comprised 94 ESBL-
producing isolates and 71 ESBL-negative isolates that were
resistant to oxyimino-cephalosporins. The ESBL-producing
isolates were chosen to include a wide diversity of ESBLs
produced by different species, with each isolate producing
only one ESBL. The ESBL-negative isolates included isolates
that overproduced the intrinsic AmpC and OXY enzymes. The
different b-lactamases were identified using PCR methods
described previously [6–9]. E. coli ATCC 25922, E. coli ATCC
35218 and K. pneumoniae ATCC 700603 were used as quality
control strains. All the tests were performed blind, with the
test inoculum for each isolate being prepared from a plate
culture on the same day.
Synergy test
The double-disk-diffusion test, also called the synergy test,
was performed as recommended by the Comite´ de l’Antibio-
gramme de la Socie´te´ Franc¸aise de Microbiologie (CA-SFM)
(http://www.sfm.asso.fr). Antibiotic disks containing ceftazi-
dime (30 lg), cefotaxime (30 lg), cefepime (30 lg) or aztreo-
nam (30 lg) were placed on a plate, 30 mm (centre to centre)
from an amoxycillin–clavulanate (20 lg ⁄ 10 lg) disk. The inter-
disk distance was increased to 45 mm for Proteus and Provi-
dencia isolates, as recommended by the CA-SFM. After over-
night incubation at 37C, an extension of the edge of an
antimicrobial inhibition zone towards the disk containing
clavulanate was considered to indicate synergy.
CLSI phenotypic confirmatory test
The CLSI disk-diffusion confirmatory test was performed by
comparing the inhibition zone diameters given by 30-lg
cefotaxime vs. 30-lg cefotaxime plus 10-lg clavulanate disks,
and 30-lg ceftazidime vs. 30-lg ceftazidime plus 10-lg
clavulanate disks. A ‡5 mm increase between the zone
diameters for the cephalosporin disks and their respective
cephalosporin–clavulanate disks confirms ESBL production
[5]. This CLSI phenotypic confirmatory test is currently vali-
dated only for E. coli, K. pneumoniae, K. oxytoca and P. mirabilis.
Vitek-2 ESBL test
The Vitek-2 ESBL test, included in the AST-N041 card (bio-
Me´rieux, Marcy l’Etoile, France), was performed for each isolate
according to the manufacturer’s recommendations. The test
comprised a panel of six wells containing ceftazidime 0.5 mg ⁄L,
cefotaxime 0.5 mg ⁄L and cefepime 1.0 mg ⁄L, alone and in
combination with clavulanic acid (4, 4 and 10 mg ⁄L, respec-
tively). Growth was assessed quantitatively using an optical
reader. A reduction of growth in wells containing a cephalo-
sporin–clavulanate combination compared with that containing
the cephalosporin alone was considered to be indicative of
ESBL production. E. coli ATCC 25922, E. coli ATCC 35218 and
K. pneumoniae ATCC 700603 were included as quality control
strains in each run. The Vitek-2 ESBL test is currently validated
only for E. coli, K. pneumoniae and K. oxytoca. For isolates
belonging to other species, the identification was changed to
E. coli to allow the reading of the Vitek-2 ESBL test. This change
was possible because the Vitek-2 growth algorithm was the
same for all species of Enterobacteriaceae.
Statistical analysis
Sensitivity was calculated as the number of ESBL-producing
isolates showing a positive test result · 100, divided by the
number of ESBL-producing isolates. Specificity was calculated
as the number of non-ESBL-producing isolates showing a
negative test result · 100, divided by the number of non-ESBL-
producing isolates. Chi-square and Fisher’s exact tests were
used to compare proportions (Epi-Info v.6 statistical software;
CDC, Atlanta, GA, USA).
RESULTS
Double-disk synergy test
The synergy test identified 92 of the 94 ESBL-
producing isolates correctly (sensitivity 97.9%).
Among E. coli and Klebsiella spp., 71 of 73 isolates
were identified correctly as ESBL producers
(sensitivity 97.3%). False-negative results were
observed with an E. coli isolate producing SHV-
2, and a K. pneumoniae isolate producing TEM-93.
Robin et al. Vitek-2 ESBL test 149
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 148–154
The E. coli isolate producing SHV-2 displayed a
low level of resistance to oxyimino-cephalospo-
rins (MICs £1 mg ⁄L), whereas the K. pneumoniae
isolate producing TEM-93 displayed a high level
of resistance to oxyimino-cephalosporins
(MICs ‡64 mg ⁄L). Synergy was only observed
for the K. pneumoniae isolate when the inter-disk
distance was decreased from 30 to 20 mm.
Among Enterobacteriaceae other than E. coli
and klebsiellae, the synergy test detected all 21
ESBL-producing isolates (sensitivity 100%). Of
the 71 ESBL-negative isolates, 69 were identified
as non-ESBL producers (specificity 97.2%). False-
positive results were observed for a K. oxytoca
isolate that overproduced OXY, and a Serratia
marcescens isolate that produced SME-1. These
Table 1. Summary of 165 isolates of Enterobacteriaceae included in the study
Microorganism
(no. of isolates)
Extended-spectrum b-lactamase type
(no. of isolates) Non-ESBL
b-lactamase
(no. of isolates)TEM SHV CTX-M Other
Citrobacter amalonaticus (1) CTX-M-8 (1)
Citrobacter freundii (10) AmpC (10)
Enterobacter aerogenes (23) TEM-24 (1) CTX-M-8 (1)
CTX-M-9 (1)
AmpC
(20)
Enterobacter cloacae (8) AmpC
(8)
Escherichia coli (79) TEM-3 (1)
TEM-4 (1)
TEM-6 (1)
TEM-8 (1)
TEM-9 (1)
TEM-10 (1)
TEM-12 (1)
TEM-16 (1)
TEM-18 (1)
TEM-19 (1)
TEM-21 (1)
TEM-24 (1)
TEM-25 (1)
TEM-26 (1)
TEM-28 (1)
TEM-29 (1)
TEM-46 (1)
TEM-50 (1)
TEM-52 (1)
TEM-71 (1)
TEM-109 (1)
TEM-112 (1)
TEM-114 (1)
TEM-125 (1)
TEM-126 (1)
TEM-151 (1)
TEM-152 (1)
SHV-2 (1)
SHV-3 (1)
SHV-4 (1)
SHV-5 (1)
SHV-6 (1)
SHV-12 (1)
CTX-M-1 (1)
CTX-M-2 (1)
CTX-M-3 (1)
CTX-M-9 (1)
CTX-M-14 (1)
CTX-M-15 (1)
CTX-M-16 (1)
CTX-M-18 (1)
CTX-M-19 (1)
CTX-M-27 (1)
CTX-M (1)
GES-1 (1)
GES-2 (1)
GES-5 (1)
PER-1 (1)
BES-1 (1)
AmpC
(30)
Klebsiella oxytoca (3) TEM-3 (1) CTX-M (1) OXY (1)
Klebsiella pneumoniae (23) TEM-4 (1)
TEM-5 (1)
TEM-7 (1)
TEM-8 (1)
TEM-9 (1)
TEM-11 (1)
TEM-12 (1)
TEM-14 (1)
TEM-15 (1)
TEM-16 (1)
TEM-18 (1)
TEM-24 (1)
TEM-26 (1)
TEM-93 (1)
SHV-2 (2)
SHV-3 (1)
SHV-4 (1)
SHV-5 (2)
CTX-M-2 (1)
CTX-M (1)
KPC (1)
Proteus mirabilis (8) TEM-3 (1)
TEM-11 (1)
TEM-21 (1)
TEM-24 (1)
TEM-66 (1)
TEM-92 (1)
TEM-113 (1)
CTX-M-2 (1)
Proteus rettgeri (1) TEM-24 (1)
Providencia stuartii (2) TEM-24 (1)
TEM-92 (1)
Salmonella spp.(4) TEM-20 (1)
TEM-25 (1)
CTX-M-4 (1)
CTX-M-6 (1)
Serratia marcescens (3) SHV-5 (1)
SHV-12 (1)
SME-1 (1)
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two enzymes were active against certain oxyimi-
no-cephalosporins and were susceptible to
clavulanate. The results obtained using this test
are summarised in Table 2.
CLSI phenotypic confirmatory test
The CLSI phenotypic confirmatory test identified
88 of the 94 ESBL-producing isolates correctly
(sensitivity 93.6%). Among the E. coli, K. pneumo-
niae, K. oxytoca and P. mirabilis isolates, 75 of the
81 ESBL-producing isolates were identified suc-
cessfully as ESBL producers (sensitivity 92.6%),
and all of the remaining 13 Enterobacteriaceae
isolates were identified correctly as ESBL produc-
ers (sensitivity 100%). False-negative results were
observed with E. coli isolates producing TEM-19,
TEM-25, TEM-125, TEM-151 and SHV-2, and a
K. pneumoniae isolate producing SHV-2. E. coli
and K. pneumoniae isolates producing SHV-2,
and an E. coli isolate producing TEM-19, dis-
played a low level of resistance to oxyimino-
cephalosporins (MICs £1 mg ⁄L). E. coli isolates
producing TEM-125 and TEM-151 showed a
complex resistance phenotype, with reduced sus-
ceptibility to both oxyimino-cephalosporins and
to clavulanate–penicillin combinations, which
probably explains why they were not detected
as ESBL producers. The E. coli isolate producing
TEM-25 had oxyimino-cephalosporin MICs
ranging from 4 to 64 mg ⁄L, and the reason why
this isolate was not detected is unclear.
All 71 ESBL-negative strains were identified as
non-ESBL producers (specificity 100%). The
results obtained using this test are summarised
in Table 2.
Vitek-2 ESBL test
The Vitek-2 ESBL test identified 86 of the 94 ESBL-
producing isolates correctly (sensitivity 91.5%).
Among the E. coli and klebsiellae isolates in-
cluded in the study, 67 of the 73 ESBL-producing
isolates were identified correctly as ESBL produc-
ers (sensitivity 91.8%), and 19 of the other 21
ESBL-producing Enterobacteriaceae isolates were
also identified as ESBL producers (sensitivity
90.5%).
False-negative results were observed for E. coli
isolates producing TEM-19, TEM-25, TEM-151,
TEM-152 and SHV-2, for a K. pneumoniae isolate
producing TEM-93, for a Salmonella isolate pro-
ducing CTX-M-6, and for a Providencia stuartii
isolate producing TEM-24. The E. coli isolates
producing TEM-19 and SHV-2 displayed a low
level of resistance to oxyimino-cephalosporins
(MICs £1 mg ⁄L), while the E. coli isolates produc-
ing TEM-151 and TEM-152 had a complex
resistance phenotype, with resistance to both oxyi-
mino-cephalosporins and clavulanate–penicillin
combinations. Such a phenotype could explain
the difficulty in detecting ESBL production by
these isolates. The K. pneumoniae isolate producing
TEM-93 displayed a high level of resistance to
oxyimino-cephalosporins (MICs ‡64 mg ⁄L), and
was also ESBL-negative according to the CA-SFM
synergy test. The Prov. stuartii isolate had a low
level of resistance to cefotaxime and cefepime
Table 2. Comparison of the synergy test (ST), the CLSI phenotypic confirmatory test (CLSI) and the Vitek-2 ESBL test (V2)
for detecting extended-spectrum b-lactamase (ESBL) production among 94 ESBL-producing and 71 non-ESBL-producing
isolates
Species (no. of isolates)
No. of ESBL-positive
isolates identified as
No. of ESBL-negative
isolates identified as Sensitivity (%) Specificity (%)
ESBL-positive ESBL-negative ESBL-positive ESBL-negative
ST CLSI V2 ST CLSI V2ST CLSI V2 ST CLSI V2 ST CLSI V2 ST CLSI V2
Escherichia coli (79) 48 44 44 1 5 5 0 0 0 30 30 30 98 89.8 89.8 100 100 100
Klebsiella pneumoniae (23) 21 21 21 1 1 1 0 0 0 1 1 1 95.5 95.5 95.7 100 100 100
Klebsiella oxytoca (3) 2 2 2 0 0 0 1 0 0 0 1 1 100 100 100 0 100 100
Proteus mirabilis (8) 8 8 8 0 0 0 0 0 0 0 0 0 100 100 100
Citrobacter amalonaticus (1) 1 1 1 0 0 0 0 0 0 0 0 0 100 100 100
Salmonella spp. (4) 4 4 3 0 0 1 0 0 0 0 0 0 100 100 75
AmpC-producing species (47)
(Enterobacter spp.,
Citrobacter spp.,
Serratia spp.,
Providencia spp.)
8 8 7 0 0 1 1 0 0 38 39 39 100 100 87.5 97.4 100 100
Total 92 88 86 2 6 8 2 0 0 69 71 71 97.9 93.6 91.5 97.2 100 100
Robin et al. Vitek-2 ESBL test 151
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 148–154
(MICs £1 mg ⁄L), but a more typical ESBL-associ-
ated ceftazidime MIC of 16 mg ⁄L. However,
strong induction of blaAmpC by clavulanate was
observed on the synergy test plate. Thus, partially
derepressed production of AmpC could explain
why ESBL production was not detected in this
isolate. The E. coli isolate producing TEM-25, and
the Salmonella isolate producing CTX-M-6, exhib-
ited an ESBL-type level of resistance to oxyimino-
cephalosporins, with at least one MIC value in the
range 4–16 mg ⁄L. It is not clear why these isolates
were not detected by the Vitek-2 test.
All isolates with false-negative results accord-
ing to the Vitek-2 ESBL test were retested using all
methods, but the discrepancies remained in all
cases. All of the 71 ESBL-negative isolates were
identified as non-ESBL producers (specificity
100%). The results obtained using the Vitek-2
ESBL test are summarised in Table 2.
Statistical comparisons
No significant difference was observed in terms of
sensitivity (91.5% vs. 93.6% and 97.9%; p 0.57
and 0.1) and specificity (100% vs. 100% and
97.9%; p non-applicable and 0.49) between the
Vitek-2 ESBL test and the CLSI phenotypic con-
firmatory test or the synergy test, respectively. No
significant differences in sensitivity were
observed within any subgroup of Enterobacteri-
aceae: i.e., E. coli (89.8% vs. 89.8% and 98%; p 1
and 0.2), K. pneumoniae (95.5% vs. 95.5% and
95.5%, p 1) and other species (91.3% vs. 100%
and 100%; p 0.49).
DISCUSSION
This study compared the Vitek-2 ESBL test with
the synergy test and the CLSI confirmatory test
for the detection of ESBL production by a wide
variety of previously characterised non-duplicate
isolates. Such a study allowed an evaluation of
this test against a wide diversity of enzymes,
including rare and challenging ESBLs, which
could only be obtained during a lengthy multi-
centre clinical study of consecutive isolates. In the
present study of 165 non-duplicate isolates of
Enterobacteriaceae, the Vitek-2 ESBL test had a
sensitivity level for ESBL detection that was close
to that of the synergy test and the CLSI pheno-
typic confirmatory test, despite the wide variety
of b-lactamases produced (n = 68). These results
agree with those of a previous study in which the
Vitek-2 test was assessed with bacteria producing
21 different ESBLs [10].
For E. coli and Klebsiella spp., there was no
significant difference in terms of sensitivity
among the Vitek-2 ESBL test, the synergy test
and the CLSI phenotypic confirmatory test (91.8%
vs. 97.3% and 93.6%; p 0.27 and 1). The Vitek-2
ESBL test was also effective in identifying ESBLs
among AmpC-producing Enterobacteriaceae,
although its use is not validated for this group
of organisms in which ESBL detection seems to
be more difficult, especially with automated
methods. A study of Greek isolates of Enterobacter
spp. reported that the first-generation Vitek ESBL
card was positive for <10% of ESBL-producing
strains [11], and another study has indicated the
difficulties of ESBL detection in AmpC-producing
isolates using the Microscan ESBL confirmation
panels, with sensitivity ranging from 54% to 69%
[12]. The use of three oxyimino-cephalosporins,
including cefepime, could explain the higher
sensitivity (87.5%) of the Vitek-2 ESBL test among
this group of Enterobacteriaceae. Cefepime use
has also been shown to improve the sensitivity of
the synergy test among AmpC producers [13,14].
ESBL detection in the AmpC-producing group of
Enterobacteriaceae is particularly useful because
of the numerous infections caused by ESBL
producers belonging to this group [7,15,16].
However, the present study only tested eight
such isolates, and the performance of this test
should therefore be evaluated against a larger
number of isolates.
Among the wide diversity of enzymes tested,
most undetected enzymes belonged to the TEM
and SHV families. False-negative results were
observed with ESBL-producing isolates that had
a low level of resistance to oxyimino-cephalo-
sporins. Certain TEM and SHV enzymes, e.g.,
SHV-2, are known to confer such a low level of
resistance, and similar observations have been
made with other detection methods [17–19].
Detection of ESBLs belonging to the Complex
Mutant TEM (CMT) subgroup was also prob-
lematical using both the Vitek-2 ESBL test and
the CLSI phenotypic confirmatory test. Difficul-
ties in detection have also been reported for
TEM-121 (CMT-4) and TEM-151 (CMT-7) using
the synergy test, and for TEM-125 (CMT-6) using
both the synergy test and the CLSI MIC confir-
matory test [20–22].
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The present study, to the best of our
knowledge, is the first to include five CMT-type
ESBLs in an evaluation of the ESBL detection test,
i.e., TEM-50 (CMT-1), TEM-109 (CMT-5), TEM-
125 (CMT-6), TEM-151 (CMT-7) and TEM-152
(CMT-8). The study confirmed the correct identi-
fication of TEM-50 as an ESBL [23]. Of the five
isolates tested, three were correctly identified as
ESBL producers according to the Vitek-2 ESBL
test and the CLSI test, whereas all were classified
as ESBL producers according to the synergy test.
The Vitek-2 ESBL test correctly identified all of the
CTX-M-producing isolates as ESBL producers,
except for the isolate that produced the uncom-
mon enzyme CTX-M-6. The test also detected the
atypical PER-1, BES-1 and GES ESBLs. Overall,
the Vitek-2 ESBL test had a detection efficiency
close to those of the synergy test and the CLSI test
for the wide range of ESBLs tested.
The K. oxytoca isolate that overproduced the
OXY enzyme, which would often be false-positive
using other detection methods, including the
synergy test [19,24], was correctly identified as a
non-ESBL producer by the Vitek-2 ESBL test.
Thomson et al. [23] also reported the correct
identification of this enzyme using the Vitek-2
ESBL test. However, an evaluation involving a
larger number of OXY-overproducing isolates is
still required. The Vitek-2 ESBL test also identi-
fied the two isolates producing a class A carba-
penemase as non-ESBL producers, whereas the
synergy test gave a false-positive result for one of
these two isolates. A limitation of the present
study was that no isolates producing a plasmid-
mediated AmpC or metallo-b-lactamase enzyme
were included. However, these groups are not
known to give false-positive results using ESBL
detection tests.
In conclusion, the Vitek-2 ESBL test seems to be
an excellent test for routine laboratories that are
already using the Vitek-2 system because of its
easy integration into the laboratory workflow. It is
easier to perform than the double-disk synergy
test, the results of which can be reader-dependent
and rather subjective [4] . The risk of epidemic
outbreaks of infection means that the specific
detection of ESBLs is a major challenge for clinical
microbiologists [4]. As described above, detection
is often difficult, even when using reference
testing methods such as the synergy test, because
of the wide variety of ESBLs. The Vitek-2 ESBL
test is an efficient automated test that allows
accurate detection of ESBL production, and it is
therefore potentially useful for clinical microbiol-
ogists.
ACKNOWLEDGEMENTS
We thank L. Poirel for the gift of the E. coli strains producing
GES-1 and GES-2, and E. Tzelepi for the gift of the E. coli strain
producing GES-5. P. Chandezon, M. Jan and R. Perroux are
thanked for technical assistance. The AST-N041 cards were
kindly provided by bioMe´rieux. This work was supported, in
part, by a grant from Ministe`re de l’Education Nationale, de
l’Enseignement Supe´rieur et de la Recherche, Paris, France,
and by a grant from bioMe´rieux. The authors have provided
no other information concerning the existence or absence of
conflicting or dual interests.
REFERENCES
1. Livermore DM. b-Lactamases in laboratory and clinical
resistance. Clin Microbiol Rev 1995; 8: 557–584.
2. Bradford PA. Extended-spectrum b-lactamases in the 21st
century: characterization, epidemiology, and detection of
this important resistance threat. Clin Microbiol Rev 2001; 14:
933–951.
3. Paterson DL. Resistance in gram-negative bacteria:
Enterobacteriaceae. Am J Infect Control 2006; 34: S20–S28.
4. Paterson DL, Bonomo RA. Extended-spectrum b-lacta-
mases: a clinical update. Clin Microbiol Rev 2005; 18:
657–686.
5. Clinical Laboratory Standards Institute. Performance
standards for antimicrobial susceptibility testing, 15th infor-
mational supplement, M100-S15. Wayne, PA: CLSI, 2006.
6. Bonnet R, Sampaio JL, Chanal C et al. A novel class A
extended-spectrum b-lactamase (BES-1) in Serratia marces-
cens isolated in Brazil. Antimicrob Agents Chemother 2000;
44: 3061–3068.
7. De Champs C, Chanal C, Sirot D et al. Frequency and
diversity of class A extended-spectrum beta-lactamases in
hospitals of the Auvergne, France: a 2 year prospective
study. J Antimicrob Chemother 2004; 54: 634–639.
8. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emer-
gence of serine carbapenemases (KPC and SME) among
clinical strains of Enterobacteriaceae isolated in United
States medical centers: report from the MYSTIC program
(1999–2005). Diagn Microbiol Infect Dis 2006; 56: 367–372.
9. Wachino J, Doi Y, Yamane K et al. Nosocomial spread of
ceftazidime-resistant Klebsiella pneumoniae strains produc-
ing a novel class A beta-lactamase, GES-3, in a neonatal
intensive care unit in Japan. Antimicrob Agents Chemother
2004; 48: 1960–1967.
10. Spanu T, Sanguinetti M, Tumbarello M et al. Evaluation of
the new VITEK 2 extended-spectrum beta-lactamase
(ESBL) test for rapid detection of ESBL production in
Enterobacteriaceae isolates. J Clin Microbiol 2006; 44:
3257–3262.
11. Tzelepi E, Giakkoupi P, Sofianou D, Loukova V,
Kemeroglou A, Tsakris A. Detection of extended-spectrum
beta-lactamases in clinical isolates of Enterobacter cloacae
and Enterobacter aerogenes. J Clin Microbiol 2000; 38:
542–546.
Robin et al. Vitek-2 ESBL test 153
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 148–154
12. Sturenburg E, Lang M, Horstkotte MA, Laufs R, Mack D.
Evaluation of the Microscan ESBL plus confirmation panel
for detection of extended-spectrum beta-lactamases in
clinical isolates of oxyimino-cephalosporin-resistant gram-
negative bacteria. J Antimicrob Chemother 2004; 54: 870–875.
13. Sturenburg E, Sobottka I, Noor D, Laufs R, Mack D.
Evaluation of a new cefepime–clavulanate ESBL Etest to
detect extended-spectrum beta-lactamases in an Entero-
bacteriaceae strain collection. J Antimicrob Chemother 2004;
54: 134–138.
14. Gottlieb T, Wolfson C. Comparison of the MICs of cefe-
pime for extended-spectrum beta-lactamase-producing
and non-extended-spectrum beta-lactamase-producing
strains of Enterobacter cloacae. J Antimicrob Chemother 2000;
46: 330–331.
15. Yu WL, Wu LT, Pfaller MA, Winokur PL, Jones RN.
Confirmation of extended-spectrum beta-lactamase-pro-
ducing Serratia marcescens: preliminary report from
Taiwan. Diagn Microbiol Infect Dis 2003; 45: 221–224.
16. Mammeri H, Laurans G, Eveillard M, Castelain S, Eb F.
Coexistence of SHV-4- and TEM-24-producing Enterobacter
aerogenes strains before a large outbreak of TEM-24-pro-
ducing strains in a French hospital. J Clin Microbiol 2001;
39: 2184–2190.
17. Vercauteren E, Descheemaeker P, Ieven M, Sanders CC,
Goossens H. Comparison of screening methods for
detection of extended-spectrum beta-lactamases and their
prevalence among blood isolates of Escherichia coli and
Klebsiella spp. in a Belgian teaching hospital. J Clin Micro-
biol 1997; 35: 2191–2197.
18. M’Zali FH, Chanawong A, Kerr KG, Birkenhead D,
Hawkey PM. Detection of extended-spectrum beta-lacta-
mases in members of the family Enterobacteriaceae: com-
parison of the MAST DD test, the double disc and the Etest
ESBL. J Antimicrob Chemother 2000; 45: 881–885.
19. Linscott AJ, Brown WJ. Evaluation of four commercially
available extended-spectrum beta-lactamase phenotypic
confirmation tests. J Clin Microbiol 2005; 43: 1081–1085.
20. Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal
C, Bonnet R. CMT-type b-lactamase TEM-125, an emerg-
ing problem for extended spectrum b-lactamase detection.
Antimicrob Agents Chemother 2006; 50: 2043–2048.
21. Poirel L, Mammeri H, Nordmann P. TEM-121, a novel
complex mutant of TEM-type b-lactamase from Enterob-
acter aerogenes. Antimicrob Agents Chemother 2004; 48: 4528–
4531.
22. Robin F, Delmas J, Schweitzer C et al. Evolution of TEM-
type enzymes: biochemical and genetic characterization of
two new complex mutant TEM enzymes, TEM-151 and
TEM-152, from a single patient. Antimicrob Agents Chemo-
ther 2007; 51: 1304–1309.
23. Thomson KS, Cornish NE, Hong SG, Hemrick K, Herdt C,
Moland ES. Comparison of Phoenix and Vitek 2 ESBL
detection tests against E. coli and Klebsiella isolates with
well-characterized b-lactamases. J Clin Microbiol 2007; 45:
2380–2384.
24. Sanders CC, Barry AL, Washington JA et al. Detection of
extended-spectrum-beta-lactamase-producing members of
the family Enterobacteriaceae with Vitek ESBL test. J Clin
Microbiol 1996; 34: 2997–3001.
154 Clinical Microbiology and Infection, Volume 14 Number 2, February 2008
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 148–154
